A Precision Adjuvant Approach to Enhance SARS-CoV-2 Vaccines Optimized for Immunologically Distinct Vulnerable Populations

alexandrossfakianakis shared this article with you from Inoreader A Precision Adjuvant Approach to Enhance SARS-CoV-2 Vaccines Optimized for Immunologically Distinct Vulnerable Populations Via Clinical Infectious Diseases Advance Access Abstract The SARS-CoV-2 pandemic has caused significant mortality, especially among older adults whose distinct immune system reflects immunosenescence. Multiple SARS-CoV-2 vaccines have received emergency use authorization and or approval from the U.S. Food and Drug Administration, and throughout the world. However, their deployment has heighted significant limitations, such by age-dependent immunogenicity, requirements for multiple vaccine doses, refrigeration infrastructure that is not universally available, as well as waning immunity. Thus, there was, and continues to be a need for continued innovation during the pandemic given the desire for dose-sparing, formulations stable at more readily achievable temperatures, need for robust immunogenicity in vulnerable populations and development of safe and effective pediatric vaccines. In this context, optimal SARS-CoV-2 vaccines may ultimately rely on inclusion of adjuvants as they can potentially enhance p rotection of vulnerable populations and provide dose-sparing effects enabling single shot protection. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.